An Examination of Cognitive Fatigue Using Functional Neuroimaging

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Zeposia

Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.

Trial Locations (1)

07052

RECRUITING

Kessler Foundation, West Orange

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Hackensack Meridian Health

OTHER

collaborator

St. Barnabas Medical Center

OTHER

lead

Kessler Foundation

OTHER

NCT04885894 - An Examination of Cognitive Fatigue Using Functional Neuroimaging | Biotech Hunter | Biotech Hunter